Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Return on Sales (2016 - 2025)

Ani Pharmaceuticals' Return on Sales history spans 15 years, with the latest figure at 0.11% for Q4 2025.

  • For Q4 2025, Return on Sales rose 17.0% year-over-year to 0.11%; the TTM value through Dec 2025 reached 0.09%, up 12.0%, while the annual FY2025 figure was 0.09%, 12.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.11% at Ani Pharmaceuticals, down from 0.12% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.13% in Q1 2024 and bottomed at 0.4% in Q4 2021.
  • The 5-year median for Return on Sales is 0.0% (2021), against an average of 0.05%.
  • The largest YoY upside for Return on Sales was 35bps in 2022 against a maximum downside of -32bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 0.4% in 2021, then surged by 89bps to 0.04% in 2022, then soared by 120bps to 0.01% in 2023, then plummeted by -715bps to 0.05% in 2024, then soared by 307bps to 0.11% in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Return on Sales are 0.11% (Q4 2025), 0.12% (Q3 2025), and 0.04% (Q2 2025).